These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 25141243)

  • 1. The economic burden of diagnosed opioid abuse among commercially insured individuals.
    Rice JB; Kirson NY; Shei A; Enloe CJ; Cummings AK; Birnbaum HG; Holly P; Ben-Joseph R
    Postgrad Med; 2014 Jul; 126(4):53-8. PubMed ID: 25141243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Burden of Undiagnosed Opioid Abuse Among Commercially Insured Individuals.
    Kirson NY; Shei A; Rice JB; Enloe CJ; Bodnar K; Birnbaum HG; Holly P; Ben-Joseph R
    Pain Med; 2015 Jul; 16(7):1325-32. PubMed ID: 25929289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drivers of excess costs of opioid abuse among a commercially insured population.
    Scarpati LM; Kirson NY; Zichlin ML; Jia ZB; Birnbaum HG; Howard JC
    Am J Manag Care; 2017 May; 23(5):276-282. PubMed ID: 28738684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and cost of diagnosed opioid abuse in a privately insured population in the United States.
    Roland CL; Joshi AV; Mardekian J; Walden SC; Harnett J
    J Opioid Manag; 2013; 9(3):161-75. PubMed ID: 23771567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of diagnosed opioid abuse and its economic burden in the veterans health administration.
    Baser O; Xie L; Mardekian J; Schaaf D; Wang L; Joshi AV
    Pain Pract; 2014 Jun; 14(5):437-45. PubMed ID: 23809020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Economic Burden of Opioid Abuse: Updated Findings.
    Kirson NY; Scarpati LM; Enloe CJ; Dincer AP; Birnbaum HG; Mayne TJ
    J Manag Care Spec Pharm; 2017 Apr; 23(4):427-445. PubMed ID: 28345440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prevalence of diagnosed opioid abuse in commercial and Medicare managed care populations.
    Dufour R; Joshi AV; Pasquale MK; Schaaf D; Mardekian J; Andrews GA; Patel NC
    Pain Pract; 2014 Mar; 14(3):E106-15. PubMed ID: 24289539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost and comorbidities associated with opioid abuse in managed care and Medicaid patients in the United Stated: a comparison of two recently published studies.
    Ghate SR; Haroutiunian S; Winslow R; McAdam-Marx C
    J Pain Palliat Care Pharmacother; 2010 Sep; 24(3):251-8. PubMed ID: 20718646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating the costs of opioid abuse and dependence from an employer perspective: a retrospective analysis using administrative claims data.
    Rice JB; Kirson NY; Shei A; Cummings AK; Bodnar K; Birnbaum HG; Ben-Joseph R
    Appl Health Econ Health Policy; 2014 Aug; 12(4):435-46. PubMed ID: 24919646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of High-Cost Patients Diagnosed with Opioid Abuse.
    Shei A; Rice JB; Kirson NY; Bodnar K; Enloe CJ; Birnbaum HG; Holly P; Ben-Joseph R
    J Manag Care Spec Pharm; 2015 Oct; 21(10):902-12. PubMed ID: 26402390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct costs of opioid abuse in an insured population in the United States.
    White AG; Birnbaum HG; Mareva MN; Daher M; Vallow S; Schein J; Katz N
    J Manag Care Pharm; 2005; 11(6):469-79. PubMed ID: 15998164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Prevalence and Cost of Medicare Beneficiaries Diagnosed and At Risk for Opioid Abuse, Dependence, and Poisoning.
    Roland CL; Ye X; Stevens V; Oderda GM
    J Manag Care Spec Pharm; 2019 Jan; 25(1):18-27. PubMed ID: 30589633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective.
    Birnbaum HG; White AG; Reynolds JL; Greenberg PE; Zhang M; Vallow S; Schein JR; Katz NP
    Clin J Pain; 2006 Oct; 22(8):667-76. PubMed ID: 16988561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US.
    Rossiter LF; Kirson NY; Shei A; White AG; Birnbaum HG; Ben-Joseph R; Michna E
    J Med Econ; 2014 Apr; 17(4):279-87. PubMed ID: 24559196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics and treatment patterns of US commercially insured and Medicaid patients with opioid dependence or abuse.
    Wollschlaeger BA; Willson TM; Montejano LB; Ronquest NA; Nadipelli VR
    J Opioid Manag; 2017; 13(4):207-220. PubMed ID: 28953313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct Costs of Opioid Abuse in an Insured Population in the United States.
    White AG; Birnbaum HG; Mareva MN; Daher M; Vallow S; Schein J; Katz N
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1188-1198. PubMed ID: 32996392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sources of prescription opioids among diagnosed opioid abusers.
    Shei A; Rice JB; Kirson NY; Bodnar K; Birnbaum HG; Holly P; Ben-Joseph R
    Curr Med Res Opin; 2015 Apr; 31(4):779-84. PubMed ID: 25661018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioid Abuse: A Detailed Examination of Cost Drivers over a 24-Month Follow-up Period.
    Scarpati LM; Kirson NY; Jia ZB; Wen J; Howard J
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1110-1115. PubMed ID: 29083966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs of opioid abuse and misuse determined from a Medicaid database.
    McAdam-Marx C; Roland CL; Cleveland J; Oderda GM
    J Pain Palliat Care Pharmacother; 2010 Mar; 24(1):5-18. PubMed ID: 20345194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost drivers of prescription opioid abuse in commercial and Medicare populations.
    Pasquale MK; Joshi AV; Dufour R; Schaaf D; Mardekian J; Andrews GA; Patel NC
    Pain Pract; 2014 Mar; 14(3):E116-25. PubMed ID: 24268019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.